Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCHIC: Serplulimab + CAPEOX in locally advanced colon cancer
NCT06368141Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2024
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in colon cancer, sponsored by Ruijin Hospital. Started May 2024; status: recruiting.
02
Drugs
serplulimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06368141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368141.